M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing ...

The oncologist and former University of California, San Francisco, professor has long been critical of COVID-19 mandates and ...

A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while ...

Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is ...

Biopharma venture capital fundraising declined from $8.1 billion in the first quarter of 2024 to $6.5 billion in the first three months of this year, headlined by a clutch of massive funding rounds.

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...